3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Oxaliplatin
288
Capecitabine
218
Fluorouracil
212
Irinotecan
145
Leucovorin
139
Gemcitabine
124
S 1 (combination)
110
apatinib
109
Cisplatin
102
Drug Therapy
98
Bevacizumab
98
Radiotherapy
97
Paclitaxel
97
camrelizumab
89
sintilimab
79
Cetuximab
75
lenvatinib
62
Neoadjuvant Therapy
61
tislelizumab
55
Surgical Procedures, Operative
54
Sorafenib
53
Folfox protocol
53
toripalimab
52
Docetaxel
52
130-nm albumin-bound paclitaxel
47
Laparoscopy
41
HMPL-013
40
XELOX
39
Radiosurgery
36
Albumin-Bound Paclitaxel
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
brigatinib
×
Gastrointestinal
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled